Chris Raymond
Stock Analyst at Raymond James
(2.76)
# 2,011
Out of 4,996 analysts
7
Total ratings
85.71%
Success rate
15.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $28.96 | +55.39% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $12.97 | +169.85% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $81.39 | +29.01% | 1 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Strong Buy | $80 | $76.63 | +4.40% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $5.61 | +309.98% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $14.16 | +111.86% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $15.00 | +400.00% | 1 | Sep 3, 2025 |
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $28.96
Upside: +55.39%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $12.97
Upside: +169.85%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $81.39
Upside: +29.01%
Monopar Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $80
Current: $76.63
Upside: +4.40%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $5.61
Upside: +309.98%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $14.16
Upside: +111.86%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $15.00
Upside: +400.00%